In addition, components of the early (C1q, C3, C3b/iC3b) and late (C5, C5a) complement cascades and the inhibitor Factor H are increased in GLAST+ EVs in plasma from MS patients vs. controls. Here, SLC1A3 is linked to myeloid sarcoma.